Developer · United States

Pherin Pharmaceuticals, Inc.

Privately held, clinical-stage drug development company that discovers and develops proprietary synthetic neuroactive steroids called pherines, intranasally administered to engage nasal chemosensory receptors for acute treatment of neuropsychiatric and neuroendocrine conditions. Acquired by VistaGen Therapeutics in February 2023 and now a wholly owned subsidiary.

pherin.com ↗

1compound
1program
1indication
Phase 2lead asset

Phase distribution

  • Phase 21

Modality

  • Small molecule 1

Mechanism focus

Pipeline (1)

Deals & partnerships

  • ItruvoneLed by VistaGen Therapeutics, Inc.Licensee VistaGen Therapeutics, Inc.
  • Feb 2, 2023AcquisitionVistaGen Therapeutics completes acquisition of Pherin PharmaceuticalsVistaGen Therapeutics closed its acquisition of Pherin Pharmaceuticals, securing all intellectual property rights to the pherine nasal spray pipeline (including PH10/itruvone for MDD and PH94B for social anxiety disorder) and eliminating future royalty and milestone payment obligations on the licensed compounds. Pherin became a wholly owned subsidiary. Announced December 21, 2022; closed February 2, 2023.Itruvonesource ↗
  • Oct 24, 2018Option exerciseVistaGen exercises option for exclusive worldwide license to PH10 (itruvone) from PherinVistaGen Therapeutics exercised its option to acquire from Pherin Pharmaceuticals the exclusive worldwide license to develop and commercialize PH10 (itruvone), an intranasal neuroactive steroid (pherine) for major depressive disorder. Consideration was $2.0 million of VistaGen unregistered common stock (925,926 shares). Announced October 25, 2018.Itruvonesource ↗

Catalysts · 0 upcoming · 1 reported

Recently reported

Recent activity

  • Jun 21, 2023Phase changeItruvone·Major depressive disorderPhase 2Favorable safety/tolerability results from U.S. Phase 1 bridging study (single-center, randomized, double-blind, placebo-controlled, healthy adults; first dosed Jan 2023, last patient last visit Mar 2023) announced; no serious adverse events or AE discontinuations. Enables planned U.S. Phase 2B development. Program remains Phase 2 overall.source ↗
  • Dec 6, 2022Phase changeItruvone·Major depressive disorderPhase 2FDA granted Fast Track designation for development of PH10 (itruvone) to treat major depressive disorder.source ↗
  • Feb 19, 2020ReadoutItruvone·Major depressive disordermetPositive Phase 2A study of PH10 (itruvone) in MDD: statistically significant rapid-onset antidepressant effect on HAM-D-17 vs placebosource ↗

Competitive landscape

Other companies developing against Pherin Pharmaceuticals, Inc.'s targets or indications.

Leadership & advisors (8)